

*Full Length Research Paper*

# Voriconazole therapy: Associated acute kidney injury

Feng Wang<sup>1</sup>, Mei Bai<sup>1</sup>, Binghui Zhao<sup>2</sup> and Niansong Wang<sup>1\*</sup>

<sup>1</sup>Department of Nephrology and Rheumatology, the Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, China.

<sup>2</sup>Department of Radiology, The Tenth People's Hospital Affiliated to Tongji University, Shanghai 200072, China.

Accepted 11 September, 2019

**Voriconazole is a good antifungal drug, which is often used to treat aspergillosis. Little is, however, known about its renal toxicity effect. A patient with microscopic polyangiitis (MPA) and pulmonary aspergillosis treated with Voriconazole suffered from acute renal failure, which was diagnosed Voriconazole therapy-associated acute kidney injury. Finally the patient recovered. This is a case report of Voriconazole therapy-associated acute kidney injury.**

**Key words:** Voriconazole, aspergillosis, therapy-associated, acute kidney injury.

## INTRODUCTION

Acute kidney injury (AKI) is a common disease characterized by a rapid decrease in kidney function, which is often fatal. About 2-5% of hospitalized patients will develop it. In recent years drug-associated AKI is more and more reported. So it should be paid more attention. A case of Voriconazole therapy-associated AKI is reported below.

## CASE REPORT

The patient, 79 year old female, was hospitalized due to cough and expectoration with fever for 1 day. Eight months ago she began to feel fatigue and nausea and went to hospital and took relative examination. The results showed the level of serum creatinine (Scr) was 1260  $\mu\text{mol/L}$ , urea protein 4.5 g/day, antinuclear antibody (ANA) negative, perinuclear anti-neutrophil cytoplasmic antibody (pANCA) 1: 420, myeloperoxidase-ANCA (MPO-ANCA) 1:60, and the patient was then diagnosed with microscopic polyangiitis (MPA). The following therapies were applied: Methylprednisolone 40 mg qd PO, Mycophenolate Mofetil (MMF) 0.75 bid PO, and 12 times of plasma exchange combined with hemodialysis. ANCA became negative, and renal function was recovered with Scr level of 200  $\mu\text{mol/L}$ . After discharge from hospital, were applied, and follow-up visit was performed once two

Methylprednisolone 40 mg qd PO and MMF 0.75 bid PO weeks. The Scr level was stable at about 180  $\mu\text{mol/L}$ . Methylprednisolone was reduced gradually. Urine volume was between 1500~2500 ml/day. The therapeutic regimen before hospitalization included Methylprednisolone 20 mg qd PO and MMF 0.75 bid PO.

## Physical examination: T 39.9°C, Bp 150/90 mmHg

The patient was conscious, with slightly short breath, anemia appearance, as well as rough respiratory murmur and moist rales in both lungs. The heart rate was 150 bpm, and she had atrial fibrillation. The abdomen was soft and without tenderness. No pathologic reflex was found.

## Laboratory examination

Blood routine examination: WBC  $15.2 \times 10^9/\text{L}$ , N: 90%, Hb 51 g/L, PLT  $120 \times 10^9/\text{L}$ .


## Hepatic and renal function

The levels of Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) were both normal. Scr was 225  $\mu\text{mol/L}$ , blood urine nitrogen (BUN) was 6.9 mmol/L and urate (UA) was 620  $\mu\text{mol/L}$ . Blood glucose was within normal range.

\*Corresponding author. E-mail: wangniansong2008@163.com.



**Figure 1.** Thoracic X-ray. High-density shadows in right lower lung, expanded heart shadow.



**Figure 2.** Pulmonary CT scan. Consolidation and atelectasis of right lower lung, bilateral pleural effusion.

showed medium volume of peritoneal fluid.

### Diagnosis

MPA, chronic kidney disease (CKD) Stage 3 to 4, lung infection, secondary immune deficiency.

### Electrolytes

Sodium 132 mmol/L, potassium 3.8 mmol/L, chloride 102 mmol/L and carbon dioxide 19.8 mmol/L.

### Immunology

Immunoglobulin G (IgG) 3.0g/L, C-reactive protein (CRP) 203 mg/dl, ANCA negative.

### Sputum smear

*Klebsiella pneumoniae* could be detected.

### Auxiliary examination


Thoracic X-ray showed a small piece of blur shadow in the right lower lung, increased streaks in both lungs, small amount of pleural effusion in both sides (Figure 1). Lung CT scan showed high-density shadow in right lower and left upper lungs, small amount of pleural effusion in both sides (Figure 2).

### Echocardiogram

Increased left atrium and increased pulmonary artery pressure were observed. Abdomen ultrasonography scan

### TREATMENT

Support treatment, heteropathy, transfusion and infusion of albumin were used. Anti-infection protocol was clindamycin 1.8 iv qd, cefoperazone and sulbactam (2:1) 3.0 iv bid, Imipenem 0.5 iv q8h, Fluconazole 0.1 iv bid. And intravenous Gamma globulin 10.0 g qd was used. Two days later, the temperature became normal and general situation improved slightly, but there were still rales in lungs. WBC maintained within the range of  $WBC 12-15 \times 10^9/L$  and the percentage of N was higher than 85%. Refractory hyponatremia happened within the sodium level of 105 to 118 mmol/L, and epilepsy gravior happened several times. Blood gas analysis showed arterial pressure of oxygen 70 to 80 mmHg, normal pH and arterial pressure of carbon dioxide. Two weeks later, she had a bad hemoptysis with a volume of about 50ml. Emergency computed tomography (CT) scan showed high-density images in left upper lung, high-density images associated with cavities in right lower lung (Figure 3). Sputum culture showed there was *Aspergillus fumigatus*. Pulmonary Aspergillosis was considered by experts from departments of pulmonary and infection of the hospital. Then intravenous Voriconazole 0.2 qd was used as well as cefoperazone and sulbactam 3.0 bid. Twenty-four hours after the administration of Voriconazole, the urine volume reduced from 1600 to 450 ml suddenly and Scr increased. A KI was diagnosed, and continuous renal replacement therapy (CRRT) was applied every two days in order to clear inflammatory



**Figure 3.** Pulmonary CT scan. Cavity formation of right lower lung, bilateral pleural effusion.



**Figure 4.** Pulmonary CT scanning. Decreased cavity, bilateral pleural effusion.

media and maintain acid-base equilibrium. Epileptic seizure never attack again after initial CRRT. Re-examination with CT after three weeks showed that the shadow in right lung was absorbed gradually and the size of cavities decreased (Figure 4). Then Voriconazole was applied with a level of 0.2 g/day PO, and other antibiotics were stopped gradually. After oral Voriconazole treatment, urine volume turned to be about 1500 ml/day. Then CRRT was stopped in the 4th week.

## OUTCOME

The patient's general status turned out to be better. Body temperature became normal. Blood routine examination maintained normal. Signs in lungs vanished gradually. Rales nearly disappeared finally. She was discharged from hospital on 28th November, 2005. After the discharge, she maintained to take Voriconazole 0.2/day for a total duration of 8W. In January of 2007, the patient

was treated with peritoneal dialysis because of end stage renal disease, and she died of chronic cardiac insufficiency in May of 2009.

## DISCUSSION

MPA is a common systemic small-vessel vasculitis with a various clinical symptoms. It can be slight, or attacked acutely and progressed into renal failure rapidly, often associated with respiratory failure. Besides renal failure, secondary infection and lung lesions are major causes of death (Watts, 2010). Infection in lungs often happens in patients with MPA, not only because MPA can involve lungs directly, but also glucocorticoid and immunosuppressants are often used (Itabashi et al., 2010; Bosch, 2010). The patient reported here had a lung infection during MPA treatment, and was diagnosed as pulmonary aspergillosis. The infection could be related to the primary disease and administration of glucocorticoid and immunosuppressants (Silva et al., 2010; Wang et al., 2010). When the routine anti-infection therapy was not effective, she was treated with Voriconazole and cured finally.

Voriconazole has potential anti-fungus activity, and is of great use for severe fungal pneumonia. During treatment of severe pneumonia, purification of blood especially CRRT can clear inflammatory media, and modify resisting electrolyte imbalances rapidly and effectively. It can be used to treat electrolyte imbalances related with anti-infection, lower pulmonary exudate and pleural effusion, improve hypoxemia, and maintain homeostasis. It is likely to be decisive for prognosis. Support treatment is also very important. Once a patient was suspected with fungal infection, anti-fungus therapies should be applied as soon as possible. If general anti-fungus drugs (e.g. Diflucan) were not effective, non-sensitive fungi should be considered. Voriconazole should be applied to severe patients as early as possible, thus improving prognosis significantly.

The Chinese data about Voriconazole is limited currently. There is no report yet about apparent nephrotoxicity. Sulfobutylether- $\beta$ -cyclodextrin (SBECD), the vehicle in vein of intravenous Voriconazole, can accumulate due to renal insufficiency, but the outcome is not clear. Therefore, intravenous Voriconazole should be applied with caution (Vfend® (voriconazole) Package Insert; FDA Antiviral Drugs Advisory Committee Briefing Document for Voriconazole, 2002). There were some pharmacokinetics studies about administration of Voriconazole in uremic patients for alternative treatment (Peng and Lien, 2005; Fuhrmann et al., 2007), but it is still unclear about dosage adjustment in patients with chronic renal disease (von Mach et al., 2006; Heinz et al., 2011). As the patient in this report had baseline chronic renal disease and oliguria happened after intravenous administration of Voriconazole, so dose reduction was

conducted based on experience. Thereafter oral Voriconazole was applied and her urine volume got normal, as proved Voriconazole could cause oliguria, especially for patients with chronic renal diseases. Of course it deserved further study whether it is a direct effect of Voriconazole or SBECD. The 0.2 g/day level of Voriconazole had a strong anti-fungal efficacy, and the clinical symptoms disappeared rapidly in this report. Therefore, oral Voriconazole is likely a good alternative for treatment of resisting fungal infection, and no obvious impairment to renal function was found (Figures 1 to 4).

## REFERENCES

- Watts RA (2010). Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: Time to RAVE? *Nat. Rev. Rheumatol.*, 6(3): 127-128.
- Itabashi M, Takei T, Yabuki Y, Suzuki H, Ando M, Akamatsu M, Yamazaki M, Mitobe M, Watanabe Y, \*Mochizuki T, Nitta K (2010). Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan. *Nephron Clin. Pract.*, 115(1): c21-c27.
- Bosch X (2010). Inflammation: Rituximab in ANCA vasculitis and lupus: Bittersweet results. *Nat. Rev. Nephrol.*, 6(3): 137-139.
- Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, Fervenza FC (2010). Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. *Clin. J. Am. Soc. Nephrol.*, 5(3): 445-453.
- Wang F, Wang N, Li J (2010). Analysis on the infection among patients with nephrotic syndromes and systemic vasculitis treated with mycophenolate mofetil. *Clin. Rheumatol.*, 29(9): 1073-1074.
- Peng LW, Lien YH (2005). Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. *Am. J. Kidney. Dis.*, 45: 162-166.
- Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, Holzinger U, Kitzberger R, Thalhammer F (2007). Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. *J. Antimicrob. Chemother.*, 60: 1085-1090.
- von Mach MA, Burhenne J, Weilemann LS (2006). Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. *BMC Clin. Pharmacol.*, 6: 6.
- Heinz WJ, Silling G, Böhme A (2011). Utilisation, efficacy and safety of voriconazole: Prospective, non-interventional study on treatment of IFIs in clinical practice. *Curr. Med. Res. Opin.*, 27(2): 335-342.